Pfizer 2015 Annual Report Download - page 128

Download and view the complete annual report

Please find page 128 of the 2015 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 134

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
2015 Financial Report
127
Significant Product Revenues
The following table provides detailed revenue information:
Year Ended December 31,
(MILLIONS OF DOLLARS) 2015 2014 2013
INNOVATIVE PRODUCTS BUSINESS(a) $ 26,758 $ 24,005 $ 23,602
GIP(a) $ 13,954 $ 13,861 $ 14,317
Lyrica GIP(b) 3,655 3,350 2,965
Enbrel (Outside the U.S. and Canada) 3,333 3,850 3,774
Viagra GIP(c) 1,297 1,181 1,180
BeneFIX 752 856 832
Chantix/Champix 671 647 648
Genotropin 617 723 772
Refacto AF/Xyntha 533 631 602
Xeljanz 523 308 114
Toviaz 267 288 236
BMP2 232 228 209
Somavert 218 229 217
Rapamune 197 339 350
Alliance revenue GIP(d) (o) 1,254 762 1,878
All other GIP(e) 405 469 540
VOC(a) $ 12,803 $ 10,144 $ 9,285
Prevnar family(f) 6,245 4,464 3,974
Sutent 1,120 1,174 1,204
Ibrance 723 ——
Xalkori 488 438 282
Inlyta 430 410 319
FSME-IMMUN/TicoVac 104 ——
All other V/O(e) 298 211 164
Consumer Healthcare 3,395 3,446 3,342
ESTABLISHED PRODUCTS BUSINESS(g) $ 21,587 $ 25,149 $ 27,619
Legacy Established Products(h) $ 11,745 $ 13,016 $ 14,089
Lipitor 1,860 2,061 2,315
Premarin family 1,018 1,076 1,092
Norvasc 991 1,112 1,229
Xalatan/Xalacom 399 495 589
Zoloft 374 423 469
Relpax 352 382 359
EpiPen 339 294 273
Effexor 288 344 440
Zithromax/Zmax 275 311 387
Xanax/Xanax XR 224 253 276
Cardura 210 263 296
Neurontin 196 210 216
Diflucan 181 208 238
Tikosyn 179 141 119
Depo-Provera 170 201 191
Unasyn 118 96 84
All other Legacy Established Products(e), (o) 4,571 5,145 5,516
Peri-LOE Products(i) $5,326$8,855 $ 10,151
Lyrica GEP(b) 1,183 1,818 1,629
Zyvox 883 1,352 1,353
Celebrex 830 2,699 2,918
Pristiq 715 737 698
Vfend 682 756 775
Viagra GEP(c) 411 504 701
Revatio 260 276 307
All other Peri-LOE Products(e) 362 714 1,770
Sterile Injectable Pharmaceuticals(j) $3,944$3,277 $3,378
Medrol 402 381 398
Sulperazon 339 354 309
Fragmin 335 364 359
Tygacil 304 323 358
All other Sterile Injectable Pharmaceuticals(e) 2,563 1,855 1,954
Infusion Systems(k) $403$—$ —
Biosimilars(l) $63$—$ —
Other Established Products(m) $106$—$ —
OTHER(n) $506$ 451 $ 364
Revenues $ 48,851 $ 49,605 $ 51,584
Total Lyrica(b) $4,839$5,168 $4,595
Total Viagra(c) $1,708$1,685 $1,881
Total Alliance revenues(o) $1,312$ 957 $ 2,628